The Effects of Moxibustion on Ulcerative Colitis
Efficacy of Moxibustion Treatment on Patients With Ulcerative Colitis
1 other identifier
interventional
60
1 country
1
Brief Summary
To investigate the mechanism and effects of moxibustion on patients with ulcerative colitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2016
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 23, 2016
CompletedFirst Submitted
Initial submission to the registry
September 25, 2016
CompletedFirst Posted
Study publicly available on registry
October 12, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedMarch 18, 2021
June 1, 2018
2.4 years
September 25, 2016
March 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Mayo score
Assay for the ulcerative colitis desease activity index. It is constructed by four scales, Including stool frequency、rectal bleeding、mucosal appearance at endoscopy and physician rating of disease activity. Every scale can be scored with o ,1 ,2 or 3 according to the activity index of scale. Scores should be compared to previous scores taken for a patient. The higher the score (minimum 0 point and maximum 12 points), the more severe the ulcerative colitis.
3 months
Secondary Outcomes (17)
MRI
3 months
functional MRI
3 months
mucosal pathology; Baron score;
3 months
Inflammatory Bowel Disease Questionnaire(IBDQ)
3 months
Laboratory tests for disease activity: C-reaction protein
3 months
- +12 more secondary outcomes
Other Outcomes (1)
Safety Assessment
3 months
Study Arms (2)
Herb-partitioned moxibustion
EXPERIMENTALDrug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
Sham herb-partitioned moxibustion
SHAM COMPARATORDrug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
Interventions
Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Eligibility Criteria
You may qualify if:
- Meet the diagnosis of UC
- Mayo ≤10
- Patients do not receive any medicine, or if they are receiving medicine, it should be aminosalicylates and/or prednisone (dose ≤15mg and have taken at least 1 month), and must kept the same dose as before throughout the trial;
- Patients should have not received antibiotic, biologicals within 3 months prior to entering the study;
- Signing a written informed consent.
You may not qualify if:
- Patients with cardiac, encephalic, hepatic, nephric, hematopoietic system, psychotic or any other serious diseases;
- Pregnancy or lactation;
- The psychiatric patients;
- Current or prior history of neurosurgery, head injury, cerebrovascular insult, or brain trauma involving loss of consciousness;
- Learning disability;
- Claustrophobia;
- Presence of metallic implants in the body;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Outpatient department of Shanghai Research Insititute of Acupuncture and Meridian
Shanghai, Xuhui, 20000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Huangan Wu, Doctor
Shanghai Institute of Acupuncture-Moxibustion and Meridian, Shanghai University of Traditional Chinese Medicine.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 25, 2016
First Posted
October 12, 2016
Study Start
August 23, 2016
Primary Completion
December 31, 2018
Study Completion
December 31, 2019
Last Updated
March 18, 2021
Record last verified: 2018-06